1 Study Coverage
1.1 Next Generation Cancer Diagnostics Revenue in Next Generation Cancer Diagnostics Business (2017-2022) & (US$ Million) Introduction
1.2 Global Next Generation Cancer Diagnostics Outlook 2017 VS 2022 VS 2028
1.2.1 Global Next Generation Cancer Diagnostics Market Size for the Year 2017-2028
1.2.2 Global Next Generation Cancer Diagnostics Market Size for the Year 2017-2028
1.3 Next Generation Cancer Diagnostics Market Size, United States VS Global, 2017 VS 2022 VS 2028
1.3.1 The Market Share of United States Next Generation Cancer Diagnostics in Global, 2017 VS 2022 VS 2028
1.3.2 The Growth Rate of Next Generation Cancer Diagnostics Market Size, United States VS Global, 2017 VS 2022 VS 2028
1.4 Next Generation Cancer Diagnostics Market Dynamics
1.4.1 Next Generation Cancer Diagnostics Industry Trends
1.4.2 Next Generation Cancer Diagnostics Market Drivers
1.4.3 Next Generation Cancer Diagnostics Market Challenges
1.4.4 Next Generation Cancer Diagnostics Market Restraints
1.5 Study Objectives
1.6 Years Considered
2 Next Generation Cancer Diagnostics by Type
2.1 Next Generation Cancer Diagnostics Market Segment by Type
2.1.1 Next Generation Sequencing
2.1.2 qPCR & Multiplexing
2.1.3 DNA Microarrays
2.1.4 Others
2.2 Global Next Generation Cancer Diagnostics Market Size by Type (2017, 2022 & 2028)
2.3 Global Next Generation Cancer Diagnostics Market Size by Type (2017-2028)
2.4 United States Next Generation Cancer Diagnostics Market Size by Type (2017, 2022 & 2028)
2.5 United States Next Generation Cancer Diagnostics Market Size by Type (2017-2028)
3 Next Generation Cancer Diagnostics by Application
3.1 Next Generation Cancer Diagnostics Market Segment by Application
3.1.1 Hospitals
3.1.2 Clinics
3.1.3 Others
3.2 Global Next Generation Cancer Diagnostics Market Size by Application (2017, 2022 & 2028)
3.3 Global Next Generation Cancer Diagnostics Market Size by Application (2017-2028)
3.4 United States Next Generation Cancer Diagnostics Market Size by Application (2017, 2022 & 2028)
3.5 United States Next Generation Cancer Diagnostics Market Size by Application (2017-2028)
4 Global Next Generation Cancer Diagnostics Competitor Landscape by Company
4.1 Global Next Generation Cancer Diagnostics Market Size by Company
4.1.1 Top Global Next Generation Cancer Diagnostics Companies Ranked by Revenue (2021)
4.1.2 Global Next Generation Cancer Diagnostics Revenue by Player (2017-2022)
4.2 Global Next Generation Cancer Diagnostics Concentration Ratio (CR)
4.2.1 Next Generation Cancer Diagnostics Market Concentration Ratio (CR) (2017-2022)
4.2.2 Global Top 5 and Top 10 Largest Companies of Next Generation Cancer Diagnostics in 2021
4.2.3 Global Next Generation Cancer Diagnostics Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
4.3 Global Next Generation Cancer Diagnostics Headquarters, Revenue in Next Generation Cancer Diagnostics Business (2017-2022) & (US$ Million) Type
4.3.1 Global Next Generation Cancer Diagnostics Headquarters and Area Served
4.3.2 Global Next Generation Cancer Diagnostics Companies Revenue in Next Generation Cancer Diagnostics Business (2017-2022) & (US$ Million) Type
4.3.3 Date of International Companies Enter into Next Generation Cancer Diagnostics Market
4.4 Companies Mergers & Acquisitions, Expansion Plans
4.5 United States Next Generation Cancer Diagnostics Market Size by Company
4.5.1 Top Next Generation Cancer Diagnostics Players in United States, Ranked by Revenue (2021)
4.5.2 United States Next Generation Cancer Diagnostics Revenue by Players (2020, 2021 & 2022)
5 Global Next Generation Cancer Diagnostics Market Size by Region
5.1 Global Next Generation Cancer Diagnostics Market Size by Region: 2017 VS 2022 VS 2028
5.2 Global Next Generation Cancer Diagnostics Market Size by Region (2017-2028)
5.2.1 Global Next Generation Cancer Diagnostics Market Size by Region: 2017-2022
5.2.2 Global Next Generation Cancer Diagnostics Market Size by Region (2023-2028)
6 Segment in Region Level & Country Level
6.1 North America
6.1.1 North America Next Generation Cancer Diagnostics Market Size YoY Growth 2017-2028
6.1.2 North America Next Generation Cancer Diagnostics Market Facts & Figures by Country (2017, 2022 & 2028)
6.1.3 U.S.
6.1.4 Canada
6.2 Asia-Pacific
6.2.1 Asia-Pacific Next Generation Cancer Diagnostics Market Size YoY Growth 2017-2028
6.2.2 Asia-Pacific Next Generation Cancer Diagnostics Market Facts & Figures by Region (2017, 2022 & 2028)
6.2.3 China
6.2.4 Japan
6.2.5 South Korea
6.2.6 India
6.2.7 Australia
6.2.8 Taiwan
6.2.9 Indonesia
6.2.10 Thailand
6.2.11 Malaysia
6.2.12 Philippines
6.3 Europe
6.3.1 Europe Next Generation Cancer Diagnostics Market Size YoY Growth 2017-2028
6.3.2 Europe Next Generation Cancer Diagnostics Market Facts & Figures by Country (2017, 2022 & 2028)
6.3.3 Germany
6.3.4 France
6.3.5 U.K.
6.3.6 Italy
6.3.7 Russia
6.4 Latin America
6.4.1 Latin America Next Generation Cancer Diagnostics Market Size YoY Growth 2017-2028
6.4.2 Latin America Next Generation Cancer Diagnostics Market Facts & Figures by Country (2017, 2022 & 2028)
6.4.3 Mexico
6.4.4 Brazil
6.4.5 Argentina
6.5 Middle East and Africa
6.5.1 Middle East and Africa Next Generation Cancer Diagnostics Market Size YoY Growth 2017-2028
6.5.2 Middle East and Africa Next Generation Cancer Diagnostics Market Facts & Figures by Country (2017, 2022 & 2028)
6.5.3 Turkey
6.5.4 Saudi Arabia
6.5.5 U.A.E
7 Company Profiles
7.1 Cepheid
7.1.1 Cepheid Company Details
7.1.2 Cepheid Business Overview
7.1.3 Cepheid Next Generation Cancer Diagnostics Introduction
7.1.4 Cepheid Revenue in Next Generation Cancer Diagnostics Business (2017-2022)
7.1.5 Cepheid Recent Development
7.2 Koninklijke Philips N.V
7.2.1 Koninklijke Philips N.V Company Details
7.2.2 Koninklijke Philips N.V Business Overview
7.2.3 Koninklijke Philips N.V Next Generation Cancer Diagnostics Introduction
7.2.4 Koninklijke Philips N.V Revenue in Next Generation Cancer Diagnostics Business (2017-2022)
7.2.5 Koninklijke Philips N.V Recent Development
7.3 F. Hoffmann-La Roche Ltd
7.3.1 F. Hoffmann-La Roche Ltd Company Details
7.3.2 F. Hoffmann-La Roche Ltd Business Overview
7.3.3 F. Hoffmann-La Roche Ltd Next Generation Cancer Diagnostics Introduction
7.3.4 F. Hoffmann-La Roche Ltd Revenue in Next Generation Cancer Diagnostics Business (2017-2022)
7.3.5 F. Hoffmann-La Roche Ltd Recent Development
7.4 Qiagen
7.4.1 Qiagen Company Details
7.4.2 Qiagen Business Overview
7.4.3 Qiagen Next Generation Cancer Diagnostics Introduction
7.4.4 Qiagen Revenue in Next Generation Cancer Diagnostics Business (2017-2022)
7.4.5 Qiagen Recent Development
7.5 Novartis AG
7.5.1 Novartis AG Company Details
7.5.2 Novartis AG Business Overview
7.5.3 Novartis AG Next Generation Cancer Diagnostics Introduction
7.5.4 Novartis AG Revenue in Next Generation Cancer Diagnostics Business (2017-2022)
7.5.5 Novartis AG Recent Development
7.6 Abbott
7.6.1 Abbott Company Details
7.6.2 Abbott Business Overview
7.6.3 Abbott Next Generation Cancer Diagnostics Introduction
7.6.4 Abbott Revenue in Next Generation Cancer Diagnostics Business (2017-2022)
7.6.5 Abbott Recent Development
7.7 Thermo Fisher Scientific
7.7.1 Thermo Fisher Scientific Company Details
7.7.2 Thermo Fisher Scientific Business Overview
7.7.3 Thermo Fisher Scientific Next Generation Cancer Diagnostics Introduction
7.7.4 Thermo Fisher Scientific Revenue in Next Generation Cancer Diagnostics Business (2017-2022)
7.7.5 Thermo Fisher Scientific Recent Development
7.8 Opko Health
7.8.1 Opko Health Company Details
7.8.2 Opko Health Business Overview
7.8.3 Opko Health Next Generation Cancer Diagnostics Introduction
7.8.4 Opko Health Revenue in Next Generation Cancer Diagnostics Business (2017-2022)
7.8.5 Opko Health Recent Development
7.9 Myriad Genetics
7.9.1 Myriad Genetics Company Details
7.9.2 Myriad Genetics Business Overview
7.9.3 Myriad Genetics Next Generation Cancer Diagnostics Introduction
7.9.4 Myriad Genetics Revenue in Next Generation Cancer Diagnostics Business (2017-2022)
7.9.5 Myriad Genetics Recent Development
7.10 Agilent Technologies
7.10.1 Agilent Technologies Company Details
7.10.2 Agilent Technologies Business Overview
7.10.3 Agilent Technologies Next Generation Cancer Diagnostics Introduction
7.10.4 Agilent Technologies Revenue in Next Generation Cancer Diagnostics Business (2017-2022)
7.10.5 Agilent Technologies Recent Development
7.11 GE Healthcare
7.11.1 GE Healthcare Company Details
7.11.2 GE Healthcare Business Overview
7.11.3 GE Healthcare Next Generation Cancer Diagnostics Introduction
7.11.4 GE Healthcare Revenue in Next Generation Cancer Diagnostics Business (2017-2022)
7.11.5 GE Healthcare Recent Development
7.12 PerkinElmer
7.12.1 PerkinElmer Company Details
7.12.2 PerkinElmer Business Overview
7.12.3 PerkinElmer Next Generation Cancer Diagnostics Introduction
7.12.4 PerkinElmer Revenue in Next Generation Cancer Diagnostics Business (2017-2022)
7.12.5 PerkinElmer Recent Development
7.13 Genomic Health
7.13.1 Genomic Health Company Details
7.13.2 Genomic Health Business Overview
7.13.3 Genomic Health Next Generation Cancer Diagnostics Introduction
7.13.4 Genomic Health Revenue in Next Generation Cancer Diagnostics Business (2017-2022)
7.13.5 Genomic Health Recent Development
7.14 Illumina
7.14.1 Illumina Company Details
7.14.2 Illumina Business Overview
7.14.3 Illumina Next Generation Cancer Diagnostics Introduction
7.14.4 Illumina Revenue in Next Generation Cancer Diagnostics Business (2017-2022)
7.14.5 Illumina Recent Development
7.15 Hologic
7.15.1 Hologic Company Details
7.15.2 Hologic Business Overview
7.15.3 Hologic Next Generation Cancer Diagnostics Introduction
7.15.4 Hologic Revenue in Next Generation Cancer Diagnostics Business (2017-2022)
7.15.5 Hologic Recent Development
7.16 Almac Group
7.16.1 Almac Group Company Details
7.16.2 Almac Group Business Overview
7.16.3 Almac Group Next Generation Cancer Diagnostics Introduction
7.16.4 Almac Group Revenue in Next Generation Cancer Diagnostics Business (2017-2022)
7.16.5 Almac Group Recent Development
7.17 Janssen Global Services
7.17.1 Janssen Global Services Company Details
7.17.2 Janssen Global Services Business Overview
7.17.3 Janssen Global Services Next Generation Cancer Diagnostics Introduction
7.17.4 Janssen Global Services Revenue in Next Generation Cancer Diagnostics Business (2017-2022)
7.17.5 Janssen Global Services Recent Development
7.18 Sysmex Corporation
7.18.1 Sysmex Corporation Company Details
7.18.2 Sysmex Corporation Business Overview
7.18.3 Sysmex Corporation Next Generation Cancer Diagnostics Introduction
7.18.4 Sysmex Corporation Revenue in Next Generation Cancer Diagnostics Business (2017-2022)
7.18.5 Sysmex Corporation Recent Development
8 Research Findings and Conclusion
9 Appendix
9.1 Research Methodology
9.1.1 Methodology/Research Approach
9.1.2 Data Source
9.2 Author Details
9.3 Disclaimer
